Neuronal and Astroglial contribution to intellectual disability. This project is based on the functional characterization of the interactions between astroglia and neurons in the context of synaptopathies.
Innovative animal models for the discovery of candidate genes to the validation of therapeutic molecules for genito-urinary disorders.
The research infrastructure CELPHEDIA (Creation, Breeding, Phenotyping, Distribution and Archiving of model organisms) is a national network of distributed infrastructures over the French territory, to be closer to the users. Its main objective is to develop innovative, standardized and massively parallel technological approaches, in order to accelerate the understanding of the genome and to stimulate the generation of human or animal disease models. CELPHEDIA also aims to improve and harmonize procedures and protocols, which guarantee efficiency and reliability, thus facilitating national or international access to the models of interest.
EFOR network aims to promote model organisms used in France for functional studies of genes. It facilitates the use of these species by enhancing infrastructure dedicated to them.
Foundation for Rare Diseases main objectives are to link and unite stakeholders in research and care in rare diseases, and finance on the basis of tenders multi-annual research projects targeted on rare diseases, without restriction on the type of illness or disciplinary field (clinical, pathophysiological, therapeutic, social sciences and humanities).
Tefor is a distributed infrastructure composed by 11 partners, and is administrated by a single infrastructure office assisted by a board of directors.
Hepatocellular carcinoma – from molecular pathogenesis to clinical management
The project is funded by the French ARC foundation and managed by the LabEx HepSYS to provide new targets for prevention and treatment of Hepatocellular carcinoma (HCC), relevant biological models of the disease, nanocarriers for personalized treatment and optimized clinical care protocols. It will have a significant impact on the management of patients with HCC in France, Europe and beyond.